anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition containing a specific lactam compound and an anionic polymer, and capable of especially retaining a conditioning effect for a long period. SOLUTION: This hair-treating agene composition contains (A) 0.5-30wt.% of a compound of the formula [R<1> , R<2> are each H, a 1-8C alkyl, an alkenyl, an aryl, etc.; (n), (m) satisfy each the relationship: 2<=(n)+(m)<=4; etc.] and (B) 0.01-10wt.% of an anionic polymer. The compound of the formula includes N-hexypyrrolidone. The component A has a higher penetration-promoting action than those of benzyl alcohol or N-methyl or ethyl pyrrolidone which are conventional penetration-promoting agents. The component B covers hair, and is penetrated into the hair to prevent the damage of the hair and soften the hair. When hair is treated with the composition, the component A promotes the penetration of the component B into the hair.  The composition can be used in the form of a hair pack, a hair dye, a hair treating agent, a styling agent, a permanent wave agent, a hair color, a hair-bleaching agent, a shampoo, a hair rinse, etc.
The original form of the Combined Index of Severity of Fibromyalgia (ICAF) will be translated into Turkish by two Turkish mother tongue translators who also speak English in advanced level. Then these translations will be combined into one translation and translated back to English. These translations will send to 7 different health professions who had experience working with FMS patients. The pre-final version will be composed and tested on a group of patients with FMS. If necessary, readjustments will be made, and the final version will be investigated in FMS patients. Acceptability was assessed in terms of refusal rate, rates of missing responses, and administration time. Reliability was assessed using Cronbach's alpha and test-retest assessments. Re-test assessments will be conducted after one week from first assessment. Content validity was assessed by examining the floor and ceiling effects and skew of the distributions. Convergent and divergent validity was assessed by examining the Pearson's correlation coefficients. In addition, the confirmatory factor analysis will be done to evaluate the validity of ICAF. Responsiveness was determined by examining effect size (ES), standardized response means (SRM) and P values generated using Wilcoxon's test.
PURPOSE: (1) To determine the effect of concomitant ipsilateral knee pain (IKP) on short-term outcomes after hip arthroscopic treatment of femoroacetabular impingement syndrome (FAIS) and (2) to determine whether IKP would improve with surgery.
METHODS: Data between September 2021 and May 2022 were reviewed. Patients with a diagnosis of FAIS who underwent hip arthroscopy with a minimum of 1-year follow-up were included. The exclusion criteria were prior ipsilateral hip or knee surgery, hip Tönnis grade greater than 1, knee Kellgren-Lawrence grade greater than 2, hip conditions (avascular necrosis, Legg-Calvé-Perthes disease, pigmented villonodular synovitis, osteoid osteoma, synovial chondromatosis, and developmental dysplasia of the hip), and spine diseases. All patients underwent knee magnetic resonance imaging preoperatively. Preoperative and short-term (1-year) patient-reported outcomes were collected, consisting of the Hip Sports Activity Scale score, weekly sports participation, modified Harris Hip Score (mHHS), 12-component International Hip Outcome Tool (iHOT-12) score, and visual analog pain scale (VAS) scores for the hip and the ipsilateral knee. The percentages of patients achieving the minimal clinically important difference and patient acceptable symptom state (PASS) for the mHHS and iHOT-12 score were calculated. Multivariate regression analysis was performed to determine the effect of IKP severity on postoperative outcomes. Subgroup analysis was performed between patients with IKP alleviation and those without IKP alleviation.
RESULTS: Among the 107 patients included, 47 presented with preoperative IKP. Compared with patients without IKP, the IKP cohort had comparable knee structural abnormalities (all with P > .05). Still, the IKP cohort showed inferior preoperative values for the mHHS (P = .003), iHOT-12 score (P = .016), hip VAS score (P = .001), and weekly sports participation (P = .039). Postoperatively, the IKP cohort had a lower mHHS (P = .046), lower iHOT-12 score (P = .037), and lower hip VAS score (P = .003) and were less likely to achieve the PASS for the mHHS (P = .021) and iHOT-12 score (P = .049). Patients with higher knee VAS scores were less likely to achieve the PASS for the mHHS (odds ratio, 0.61; P = .023). Within the IKP group, the knee VAS score improved from 2.3 to 1.0 (P < .001). Patients with alleviated IKP showed superior postoperative iHOT-12 scores (P = .038) compared with patients with persistent IKP.
CONCLUSIONS: Concomitant IKP at baseline negatively affected preoperative status and short-term clinical outcomes after arthroscopic treatment of FAIS. Patients with IKP were less likely to meet clinical thresholds. Most patients achieved IKP alleviation postoperatively, which was associated with superior clinical outcomes.
LEVEL OF EVIDENCE: Level III, retrospective cohort study.
This is a randomized, open-label, parallel group, multicenter study to determine the effectiveness and safety of 488 mg of levofloxacin (once daily by mouth for 5 - 7 days) compared with 250 mg of cefaclor (every 8 hours for 7 - 10 days) in adults with chronic bronchitis experiencing rapid onset of worsening of symptoms caused by bacterial infection. The study consists of 3 visits: one visit for screening and enrollment, and 2 visits for assessment of safety and effectiveness (one visit on Days 3 - 5 of the study and one visit \[post-therapy\] 5 - 7 days after the last dose of the study drug). The total duration of patient participation in the study is approximately 2 weeks. Levofloxacin and cefaclor are antibacterial agents used for the treatment of many types of infections, including infections with a rapid onset and brief duration caused by bacteria. The primary assessment of effectiveness in this study is the microbiologic response to treatment (the rate of elimination of disease-causing bacteria, by patient, and by type of bacteria), 5 - 7 days after the last dose of study drug. Safety evaluations (incidence of adverse events, physical examination, laboratory tests) are performed throughout the study. The study hypothesis is that treatment with levofloxacin is at least as effective and as well tolerated as treatment with cefaclor in adult patients with chronic bronchitis experiencing sudden worsening of symptoms caused by bacterial infection. Levofloxacin 488 mg by mouth once daily for 5 - 7 days, or cefaclor 250 mg by mouth every 8 hours for 7 - 10 days.
<P>PROBLEM TO BE SOLVED: To provide a stable composition for bleaching, highly safe to a human body, and having excellent effects; and to provide an external preparation for the skin, containing the composition.  <P>SOLUTION: The composition for the bleaching contains an acidic xylo-oligosaccharide composition of a mixed composition of oligosaccharides having an uronic acid residue in one molecule of the xylo-oligosaccharide and different polymerization degrees of xylose, and having 5.0-15.0 average polymerization degree of the xylose. The acidic xylo-oligosaccharide composition is obtained by enzymically treating a lignocellulose material to provide a complex of the xylo-oligosaccharide component and a lignin component, hydrolyzing the complex with an acid to provide a xylo-oligosaccharide mixture, and separating the acidic xylo-oligosaccharide composition from the xylo-oligosaccharide mixture. Preferably, the uronic acid is glucuronic acid or 4-O-methyl-glucuronic acid. The composition for the bleaching contains 0.001-30 mass% acidic xylo-oligosaccharide.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To obtain the subject inhibitor capable of suppressing turnover sthenia of skin such as acanthosis, parakeratosis, abnormality of skin lipid metabolism, etc., caused by ultraviolet rays, etc., and normalizing skin keratinization by including a sphingosine. SOLUTION: This inhibitor contains a sphingosine (e.g. a compound of the formula or the like) being a physiologically active component existing in skin. The amount of the sphingosine formulated is, in the case of using the inhibitor as an emulsion-based external preparation for skin, 0.001-5 wt.%, and in the case of using an oily external preparation for skin comprising a liquid hydrocarbon such as squalane or the like, 0.01-10 wt.%. The sphingosine is obtained by extracting sphingolipid, etc., from a proper tissue (e.g. bovine brain or the like), hydrolyzing and extracting the hydrolyzate with an organic solvent.
Autism represents a large spectrum of diverse individuals with varying underlying genetic architectures and needs. For some individuals, a single de novo or ultrarare genetic variant has a large effect on the intensity of specific dimensions of the phenotype, while, for others, a combination of thousands of variants commonly found in the general population are involved. The variants with large impact are found in up to 30% of autistic individuals presenting with intellectual disability, significant speech delay, motor delay, and/or seizures. The common variants are shared with those found in individuals with attention-deficit/hyperactivity disorder, major depressive disorders, greater educational attainment, and higher cognitive performance, suggesting overlapping genetic architectures. The genetic variants modulate the function of chromatin remodeling and synaptic proteins that influence the connectivity of neuronal circuits and, in interaction with the environment of each individual, the subsequent cognitive and personal trajectory of the child. Overall, this genetic heterogeneity mirrors the phenotypic diversity of autistic individuals and provides a helpful bridge between biomedical and neurodiversity perspectives. We propose that participative and multidisciplinary research should use this information to understand better the assessment, treatments, and accommodations that individuals with autism and families need.
This study employs quasi-experimental design to investigate the feasibility and preliminary efficacy of the group-based ACT for family caregivers of people with dementia compared to the group-based CBT. Both interventions consist of eight sessions, each lasting about 90 minutes, through face-to-face or Zoom video conferencing over the course of four months. Family caregivers will be assigned to either the ACT or CBT interventions. Pre-, post-intervention, and 6 month follow-up measurements assess depression, anxiety, quality of life, cognitive appraisal of caregiving (i.e., subjective burden and positive aspect of caregiving), possible process factors (i.e., caregiving self-efficacy, experiential avoidance, and commitment), care recipients' behavioral and psychological symptoms of dementia (BPSD), and so on. This study also preliminarily examines the efficacy of combining psychological intervention for family caregivers (i.e., the group-based ACT/CBT) with those for their care recipients (i.e., group-based reminiscence therapy). The group-based reminiscence therapy will be held once or twice a month, each lasting about 60-90 minutes, over the course of about three months.
INTRODUCTION: Minimally invasive surgery is considered the gold standard for the treatment of gynecological diseases. Our study aims to assess the effectiveness of the new concept of ultra-low-impact laparoscopy as a combination of low-impact laparoscopy, consisting in the use of miniaturized instruments through 3-5mm ports and low-pressure pneumoperitoneum, with regional anesthesia to evaluate the perioperative outcomes.
METHODS: A cross-sectional study was performed from May 2023 to December 2023, to enroll 26 women affected by benign gynecological disease and threated by mini-invasive surgical approach. The surgical procedures were performed following the low-impact laparoscopy protocol and the regional anesthesia protocol. The postoperative pain, nausea, and vomiting and the antiemetic/analgesic intake were evaluated. Postoperative surgical and anesthesiological variables were analyzed.
RESULTS: Operative time was within 90 min (41.1 ± 17.1 mean ± standard deviation (SD)) and no conversion to laparotomy or general anesthesia was required. According to VAS score, the postoperative pain during the whole observation time was less than 3 (mean). Faster resumption of bowel motility (6.5 ± 2.1 mean ± SD) and women's mobilization (3.1 ± 0.7 mean ± SD) were observed as well as low incidence of post-operative nausea and vomit. Early discharge and patient's approval were recorded. Intraoperatively pain score was assessed on Likert scale during all stages.
CONCLUSION: Ultra-low-impact laparoscopy showed to provide a satisfying recovery experience for patients in terms of short hospital stays, cosmetic result, and pain relief, without compromising surgical outcomes. The encouraging results lead us to recruit a greater number of patients to validate our technique as a future well-established produce.
In a randomised controlled trial involving 45 patients the speed of onset of the effects of 20mls of 0.75% ropivacaine was found to be similar to that of 20mls of 0.5% bupivacaine1. However it was also found to be more efficacious at preventing 'breakthrough' pain and therefore had a lower intra-operative supplementation rate. Unfortunately the study was probably not powered adequately to confirm this finding. Bupivacaine has now largely been replaced in the this field by the less cardio-toxic stereoisomer levobupivacaine. A trial comparing 0.75% ropivacaine to 0.5% levobupivacaine and a lignocaine/adrenaline/fentanyl mixture was conducted in Singapore in 20082. It did not show a clinical difference between any of the agents. Whether the population studied is comparable to that in the UK is doubtful and it was not adequately powered to detect a difference in intra-operative supplementation rate. Local experience has shown ropivacaine 0.75% to provide a block with a rapid onset that has little requirement for supplementation intra-operatively. The need to supplement a local anaesthetic block during surgery means that the mother is experiencing a degree of pain that is unacceptable and we view this as a major consideration in choice of local anaesthetic for an epidural top-up. Whilst speed of onset is important, in that it influences the decision to delivery time of the baby, the evaluation of intraoperative supplementation will be a major focus of this trial.
Disclosed in the present invention is an application of Metrnl in diagnosis of atherosclerosis. A Metrnl-/-ApoE-/-double knockout atherosclerotic rat model and an EC-Metrnl-/-ApoE-/-atherosclerotic rat model are constructed. The experiment shows that the severity of atherosclerosis, the area of atherosclerotic plaque, and the degree of atherosclerosis and inflammatory infiltration in an aortic root of two Metrnl knockout rats are higher than a rat in a control group. The experiment shows that a vascular endothelial cell can secrete Metrnl, and the vascular endothelium and blood Metrin levels decrease during atherosclerosis, and the degree of decrease in Metrnl levels increases as the disease is exacerbated. The antithrombotic effect of a Metrnl recombinant protein does not have a species difference, and represents a dose-effect relationship on the inhibition effect of a clot contraction reaction. By comparing the function and characteristic of the Metrnl protein with a classical thrombolytic drug, it is found that the antithrombotic effect of Metrnl can reduce an adverse reaction of bleeding.
Tripartite Motif 14 (TRIM14) is an oncoprotein that belongs to the E3 ligase TRIM family, which is involved in the progression of various tumors except for non-small cell lung carcinoma (NSCLC). However, little is currently known regarding the function and related mechanisms of TRIM14 in NSCLC. Here, we found that the TRIM14 protein was downregulated in lung adenocarcinoma tissues compared with the adjacent tissues, which can suppress tumor cell proliferation and migration both in vitro and in vivo. Moreover, TRIM14 can directly bind to glutamine fructose-6-phosphate amidotransferase 1 (GFAT1), which in turn results in the degradation of GFAT1 and reduced O-glycosylation levels. GFAT1 is a key enzyme in the rate-limiting step of the hexosamine biosynthetic pathway (HBP). Replenishment of N-acetyl-d-glucosamine can successfully reverse the inhibitory effect of TRIM14 on the NSCLC cell growth and migration as expected. Collectively, our data revealed that TRIM14 suppressed NSCLC cell proliferation and migration through ubiquitination and degradation of GFAT1, providing a new regulatory role for TRIM14 on HBP.
PURPOSE: To obtain a cyclosporin preparation having high stability and improved biological availability, by using a support system containing a fatty acid triglyceride and mono-or diglyceride in combination with a hydrophilic surfactant. CONSTITUTION: This new cyclosporin preparation contains, in a medium, a support composed of (A) a cyclosporin as active ingredient, (B) a fatty acid triglyceride, (C) a glycerol fatty acid partial ester or propylene glycol or sorbitol perfect or partial ester, and (D) a surfactant >=10 in HLB number (e.g. a reaction product from natural or hardened castor oil and ethylene oxide). In this case, the component B and component C are each a transesterification product from glycerol and a vegetable oil; this preparation contains virtually no ethanol; the component A is cyclosporin or [Nva]<2> -cyclosporin, and the weight ratio A/D is (1:>=1), pref. 1:(1-25). It is preferable that the content of the component A in this preparation is 2-20 (esp. 5-15)wt.%.
The present invention relates to the control of pest insects. More specifically the invention relates to the identification, isolation and characterization of polypeptides for use in the control of pest insects. The invention thus provides insect-controlling peptides. Also provided are nucleic acids encoding such insect-controlling polypeptides and host cells and plants expressing such polypeptides. The present invention further provides compositions comprising polypeptides which are useful to combat crop pest insects in agriculture, insects which are pests for humans and animals, and house-hold pest insects. Also provided are methods for combating such pest insects.
The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
PURPOSE:To provide a remedy for renal diseases containing 24,25- dihydroxycholecalciferol as an active component. CONSTITUTION:A remedy for renal diseases can be prepared by using a 24,25- dihydroxycholecalciferol (e.g. 24R,25-dihydroxycholecalciferol, etc.) as an active component. It is administered orally, parenterally or through rectum, preferably by oral administration. It can be used in the form of tablet, powder, granule, suppository, alcoholic solution, oil solution, aqueous dispersion, etc. Dose: 0.1-100,000mug, preferably 0.5-10,000mug daily. The agent is effective to uremia, various renal insufficiency nephritis, etc.
Effective internal fixation with pedicle screw is a key factor in the success of lumbar fusion with internal fixation. Whether navigation robots can improve the efficacy and safety of screw placement is controversial. Thirty-eight patients who underwent oblique lateral lumbar interbody fusion internal fixation from March 2022 to May 2023 were retrospectively analyzed, 16 cases in the navigational robot group and 22 cases in the fluoroscopy group. Using visual analog score (VAS) for the low back and lower limbs, Oswestry Disability Index to compare the clinical efficacy of the 2 groups; using perioperative indexes such as the duration of surgery, intraoperative blood loss, intraoperative fluoroscopy times, and postoperative hospital stay to compare the safety of the 2 groups; and using accuracy of pedicle screws (APS) and the facet joint violation (FJV) to compare the accuracy of the 2 groups. Postoperative follow-up at least 6 months, there was no statistically significant difference between the 2 groups in the baseline data (P > .05). The navigational robot group's VAS-back was significantly lower than the fluoroscopy group at 3 days postoperatively (P < .05). However, the differences between the 2 groups in VAS-back at 3 and 6 months postoperatively, and in VAS-leg and Oswestry Disability Index at 3 days, 3 months, and 6 months postoperatively were not significant (P > .05). Although duration of surgery in the navigational robot group was significantly longer than in the fluoroscopy group (P > .05), the intraoperative blood loss and the intraoperative fluoroscopy times were significantly lower than in the fluoroscopy group (P < .05). The difference in the PHS between the 2 groups was not significant (P > .05). The APS in the navigation robot group was significantly higher than in the fluoroscopy group, and the rate of FJV was significantly lower than in the fluoroscopy group (P < .05). Compared with the traditional fluoroscopic technique, navigation robot-assisted lumbar interbody fusion with internal fixation provides less postoperative low back pain in the short term, with less trauma, less bleeding, and lower radiation exposure, as well as better APS and lower FJV, resulting in better clinical efficacy and safety.
A monitoring apparatus (5) that includes a sensor device (10) and an I/O device in communication with the sensor device that generates derived data using the data from the sensor device. The derived data cannot be directly detected by the associated sensors. Alternatively, an apparatus that includes a wearable sensor device and an I/O device in communication with the sensor device that includes means for displaying information and a dial for entering information. Alternatively, an apparatus for tracking caloric consumption and caloric expenditure data that includes a sensor device and an I/O device in communication with the sensor device. The sensor device includes a processor programmed to generate data relating to caloric expenditure from sensor data. Alternatively, an apparatus for tracking caloric information for an individual that utilizes a plurality of classification identifiers for classifying meals consumed by the individual, each of the classification identifiers having a corresponding caloric amount.
PURPOSE:Royal jelly which is naturally formed on a royal bed is tightly encapsulated with bee wax, as it is, to provide fresh and pure royal jelly. CONSTITUTION:A royal bed 1 is made using bee wax in a pot shape and a plurality of royal beds are fixed on a hive shelf in a certain interval. Then, larvas of queen bee, 60hr after hatching, are transferred into individual beds, respectively and the hive bed is returned into the hive house. Thus, working bees store royal jelly necessary for growing the larva and naturally cells 4 are formed toward the opening 3 of the royal bed. After a certain time, about 60hr, the hive shelf is taken out of the house and the opening of cells are closed, royal beds are removed from the hive shelf and the top part of the bed is dipped in melted bee wax, then dipped in cool water to close completely tightly by forming bee wax coating on the outer surface of the cell. Thus, pure and fresh royal jelly without exposure to outer air can be offered to consumers.